HIGHLIGHTS
· Revenue reached
· Revenue of Abilify Maintena[®] increased 23% to
· Revenue of Brintellix[®]/Trintellix[®] increased 30% to
· Revenue of Northera[®] increased 29% to
· Revenue of Rexulti[®]/Rxulti[®] increased 32% to
· Revenue in
· Revenue in International Markets increased 11% to
· Revenue in
· The four strategic brands grew by 28%, reaching
· Core EBIT reached
· EBIT reached
· Core EPS reached
· The acquisition of
· Lundbeck closed the acquisition of Abide Therapeutics in
· 2020 will be impacted by investments in launch and development activities for eptinezumab. Therefore, Lundbeck expects revenue to reach
· The Board of Directors proposes to pay a dividend of
In connection with the financial report, Lundbeck's President and CEO
"2019 was a tremendous year for Lundbeck as we executed well against our Expand and Invest to Grow strategy: Strategic brands grew substantially - up 28% over the prior year and we bolstered and reshaped our pipeline through the acquisitions of
We will continue to build out a robust pipeline, to deliver important new medicines for patients and deliver sustainable value for all our stakeholders, positioning Lundbeck strongly for the foreseeable future."
DKK million FY 2019 FY 2018 Growth
Core Revenue* 17,036 18,117 (6%)
Core EBIT* 4,976 6,158 (19%)
Core EPS* 19.46 23.71 (18%)
Core EBIT margin* 29.2% 34.0% -
Reported Revenue 17,036 18,117 (6%)
Reported EBIT 3,608 5,301 (32%)
Reported EPS 13.42 19.66 (32%)
Reported EBIT margin 21.2% 29.3% -
*For definition of the measures "Core Revenue", "Core EBIT" and "Core EPS", see note 3 Core reporting
Ottiliavej 9, 2500 Valby,
+45 3630 1311
info@lundbeck.com
https://news.cision.com/h--lundbeck-a-s/r/strong-momentum-with-28--growth-across-all-strategic-brands-in-2019--for-2020--lundbeck-expects-reve,c3028776
https://mb.cision.com/Main/18215/3028776/1189123.pdf
(c) 2020 Cision. All rights reserved., source